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The first hematopoietic stemcells (HSCs) that engraft
irradiated adult mice arise in the aorta-gonad-meso-
nephros (AGM) on embryonic day 11.5 (E11.5). How-
ever, at this stage, there is a discrepancy between the
apparent frequency of HSCs depicted with imaging
and their rarity when measured with limiting dilution
transplant. We have attempted to reconcile this dif-
ference using neonatal recipients, which are more
permissive for embryonic HSC engraftment. We
found that embryonic HSCs from E9.5 and E10.5
preferentially engrafted neonates, whereas develop-
mentally mature, definitive HSCs from E14.5 fetal
liver or adult bone marrow (BM) more robustly en-
grafted adults. Neonatal engraftment was enhanced
after treating adult BM-derived HSCs with interferon.
Adult BM-derived HSCs preferentially homed to
the liver in neonatal mice yet showed balanced
homing to the liver and spleen in adults. These find-
ings emphasize the functional differences between
nascent and mature definitive HSCs.
INTRODUCTION
According to the classical definition, a definitive hematopoietic
stem cell (HSC) reconstitutes multilineage hematopoiesis long-
term in irradiated adult primary transplant recipients and can
be serially passed into secondary recipients, indicating the
capacity for both self-renewal and multilineage differentiation
(Becker et al., 1963; Siminovitch et al., 1963; Till and McCulloch,
1961; Wu et al., 1968). Under that definition, the first transplant-
able murine HSC emerges in vivo in the aorta-gonad-meso-
nephros (AGM) at embryonic day 11.5 (E11.5; de Bruijn et al.,
2000; Kumaravelu et al., 2002; Medvinsky and Dzierzak, 1996;
Mu¨ller et al., 1994; Taylor et al., 2010). HSCs then migrate to
the fetal liver (FL) and rapidly divide to build up the stem cell
pool. Ultimately, HSCs populate the developing bone marrow
(BM), where they become quiescent once homeostasis is
reached in the postnatal period. Interaction with specific nichesDeveduring development allows embryonic HSCs tomature into adult
HSCs (Schofield, 1978; Wineman et al., 1996).
The surface antigen profile of the engrafting cell at E11.5, as
identified by transplantation, is vascular endothelial (VE)-
cadherin+ CD45+ CD34 cKitlow Sca1+ CD31low (Taoudi et al.,
2005, 2008). Imaging techniques coupled with the cell surface
profile of the engrafting cell have provided insight into the
emergence of the definitive HSC (Boisset et al., 2010; Kissa
and Herbomel, 2010; Taoudi and Medvinsky, 2007; Yokomizo
and Dzierzak, 2010). Imaging has revealed hundreds of c-Kit+
clusters in E11.5 AGM, implying a discrepancy in the quantity
of potential HSCs identified with imaging relative to the fre-
quency defined with limiting dilution transplantation in adult
recipients.
Analysis of emerging hematopoietic cells in the AGM at E10.5
shows 1.7 Sca1+ c-Kit+ CD31+ CD41+ cells per embryo (Boisset
et al., 2010). Transplantation has revealed that E10.5 AGM
cells are capable of rare long-term multilineage repopulation of
wild-type adult recipients (3% of transplanted animals) and
more robust repopulation in immunodeficient adult recipients,
indicating that the host environment plays a critical role in detec-
tion of nascent HSCs (Bertrand et al., 2005; Mu¨ller et al., 1994;
North et al., 2002). Interestingly, VE-cadherin+ CD45 cells
from E10.5 AGM robustly reconstitute wild-type adult recipients
after 4 days of ex vivo culture, further suggesting that there are
cells in the AGM at E10.5 with enhanced potential to engraft if
cultured under proper conditions (Rybtsov et al., 2011).
Before E10.5, the tissues of the para-aortic splanchnopleura
(PSp) contain progenitors that are primed to give rise to the
definitive HSC, as per the classical definition (Cumano et al.,
2000, 2001; Mu¨ller et al., 1994). A population from E9.5 PSp
has been reported to engraft immunodeficient adult recipients
and wild-type neonatal recipients (Kieusseian et al., 2012; Miz-
uochi et al., 2012; Yoder et al., 1997a). Neonatal engraftment
has also been observed from E9.0 yolk sac (Yoder et al., 1996,
1997b), suggesting that the neonate may be more permissive
for engraftment of early embryonic HSCs. Interestingly, we
found that definitive adult HSCs engraft less robustly in the
neonate relative to the adult. In this study, we quantified nascent
definitive HSCs in the earliest intraembryonic tissues to date
and identified the context in which HSCs from different develop-
mental stages will engraft.lopmental Cell 29, 621–628, June 9, 2014 ª2014 Elsevier Inc. 621
Figure 1. Neonates Are Only More Permis-
sive for Engraftment of Early Embryonic
HSCs
(A) Adult (square) and neonatal (circle) recipients
were both transplanted with 1 ee of whole E11.5
AGM. See also Figure S2.
(B) Secondary transplants were carried out for pri-
mary recipients engrafted with early embryonic
HSCs.
(C and D) Neonatal recipients were transplanted
with limiting doses of (C) whole E10.5 AGM and (D)
whole E9.5 PSp. See also Figure S1.
(E) Neonatal (circle) and adult (square) recipients
were transplanted with 100 adult BM LT-HSCs.
*Whereas in three neonatal recipients we detected
a robust signal in the peripheral blood at a single
time point of 18 weeks in one experiment, sub-
stantially lower donor chimerism was observed in
these mice at the next time point of 23 weeks, and
no other experiments showed this phenomenon,
leading us to conclude that these data may have
been a spurious experimental artifact.
(F) Neonatal (circle) and adult (square) recipients
were transplanted with 100 E14.5 FL LT-HSCs.
(G) Neonatal recipients were transplanted with 50
neonatal liver LT-HSCs (triangle) and 50 neonatal
BM LT-HSCs (diamond). The numbers in the graph
legends reflect the number of animals engrafted
over the number of animals transplanted.
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Quantification of Robust Reconstitution of Neonates
with Early Embryonic Tissues
We first compared engraftment of neonates and adults with cells
from E11.5 AGM, the earliest population reported to engraft wild-
type adult recipients. Neonatal recipients were more robustly
engrafted than adult recipients with similar conditioning.
Whereas seven of nine neonatal recipients were engrafted with
1 embryo equivalent (ee), at most three of six adult recipients
receiving sublethal irradiation and no helper cells were engrafted
at low levels (Figure 1A; Table S1 available online). Three of 11
neonates transplanted with 0.25 ee showed long-term engraft-622 Developmental Cell 29, 621–628, June 9, 2014 ª2014 Elsevier Inc.ment (Figures S1A and S1B). Secondary
transplants demonstrated donor HSC
self-renewal when taken from primary
animals with multilineage reconstitution
(Figure 1B), but three primary recipients
with long-lived myeloid biased lineage
skewing did not engraft secondary recipi-
ents, and thus were not engrafted with
a self-renewing HSC (Figure S1B). We
also compared neonatal engraftment with
E11.5 AGM to the current gold standard
of lethally irradiated adult recipients re-
ceiving helper cells. Only one of eight adult
mice was engrafted (Table S1). Before
quantitative analysis, these data suggest
the neonatal transplant assay is a more
permissive functional test for early embry-
onic HSCs than the gold standard assay.VE-cadherin+ CD45+ cells from E11.5 AGM have been re-
ported to engraft adult recipients (Taoudi et al., 2005). Similarly,
we found that the VE-cadherin+ CD45+ but not the VE-cadherin+
CD45 compartment engrafted neonates, thus demonstrating
that neonates and adults are engrafted with the same population
from E11.5 AGM (Figure S2B). However, the predicted repopu-
lating cell frequency was higher in neonatal than adult recipients.
Using the neonatal transplant model, limiting dilution analysis
(LDA) predicted one repopulating cell in 0.935 ee, thus quanti-
fying the sensitivity of the neonatal system for engraftment
of embryonic HSCs (Table 1). In our hands using the adult
transplant model with 300,000 helper cells, LDA predicted one
repopulating cell in 5.7 ee of E11.5 AGM, whereas the published
Table 1. Early Embryonic but Not Adult-like HSCs Prefer Neonatal Recipients
Donor Recipient
Helper
Cell Dose
Estimated Repopulating
Cell Frequency
Frequency
Upper Limit
Frequency
Lower Limit
Fit Single-Hit
Model p Value
BM LT-HSCs adult 300,000 1/13.1 cells 1/6.19 1/27.7 0.96 3.33 3 108
neonate none 1/177 cells 1/100 1/313 1.2
FL LT-HSCs adult 300,000 1/25.7 cells 1/13.8 1/47.6 0.55 3.07 3 104
neonate none 1/114 cells 1/66.9 1/195 0.91
E11.5 AGM adult 20,000 1/0.538 ee 1/0.24 1/1.2 4.46 ND
300,000 1/5.7 ee 1/2.16 1/15 2.6 5.12 3 108
neonate none 1/0.935 ee 1/0.624 1/1.4 0.74
E10.5 AGM adult 300,000 ND ND ND ND ND
neonate none 1/2.84 ee 1/1.6 1/5.02 0.71
E9.5 PSp adult 300,000 ND ND ND ND ND
neonate none 1/44.8 ee 1/18.4 1/109 0.212
LDA of reconstitution of neonatal and adult recipients with adult BM LT-HSCs, E14.5 FL LT-HSCs, whole E11.5 AGM, whole E10.5 AGM, and whole
E9.5 PSp. The upper and lower limits provide the 95% confidence interval for the repopulating cell frequency. The goodness of fit tests how well the
data fit the single-hit model that one repopulating cell will give a positive signal. A value of 1 suggests a good fit, less than 1 suggests heterogeneity in
the donor cell population, and greater than 1 suggests amulti-hit model in which recipients are hypersensitive to the given dose of donor cells; p values
are between neonatal and adult recipients transplanted with the same donor population and were calculated by the LDA algorithm. ND, not deter-
mined. See also Table S1.
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ing cell per ee (Kumaravelu et al., 2002; Table 1). When we repli-
cated the conditions from Kumaravelu et al. using 20,000 helper
cells, the calculated frequency was one repopulating cell in
0.538 ee (Table 1). Thus, our experimental quantifications reveal
sensitivity in the adult transplant model to helper dose and no
preference of HSCs at E11.5 for neonatal recipients.
We then evaluated the engraftment potential of newly speci-
fied HSCs from earlier stages of ontogeny. Neonates showed
robust, long-term, multilineage reconstitution from 4 ee to 1 ee
of unfractionated E10.5 AGM (30–39 somites; Figures 1C and
Figure S1C). At 18 weeks posttransplant, three of five recipients
receiving 4 ee, five of ten receiving 2 ee, and five of ten receiving
1 ee showed multilineage engraftment with an average of 28%,
22%, and 11% donor contribution, respectively. No neonates
were engrafted with 0.5 ee. In comparison, no engraftment
was observed in adult recipients receiving up to 7 ee with as
few as 20,000 helper cells (Table S1). Secondary transplants
demonstrated self-renewal capacity of the repopulating donor
cells from E10.5 AGM (Figure 1B). LDA predicted one repopulat-
ing cell in 2.84 ee of E10.5 AGM when using the neonatal trans-
plant model (Table 1), indicating that the repopulating cell is less
abundant in the AGM at E10.5 than it is at E11.5. These data
establish that whole E10.5 AGM robustly reconstitutes neonatal
but not adult recipients, and demonstrate the existence of an
HSC capable of long-term multilineage reconstitution in the
AGM of some embryos as early as E10.5.
When we examined reconstitution potential from even earlier
in ontogeny, we detected long-term multilineage donor chime-
rism from unfractionated E9.5 PSp (16–26 somites) transplanted
into neonates in doses from 8 ee to 1 ee (Figure 1D and Fig-
ure S1D). At 18 weeks posttransplant, one of 16 recipients
receiving 8 ee, two of five receiving 5 ee, and two of 13 receiving
1 ee were engrafted at an average of 15%, 5%, and 2%, respec-
tively. Curiously, mice engrafted with E9.5 PSp showed an earlyDeveB cell skewing, which was not as pronounced in neonates
engrafted with E10.5 AGM and not seen with E11.5 AGM (Fig-
ure S1D). LDA predicted one repopulating cell in 44.8 ee of
E9.5 PSp (Table 1). Secondary transplants confirmed that the
engrafting cell from E9.5 PSp was truly a self-renewing stem
cell (Figure 1 B). These findings provide additional conclusive
evidence for the existence of an intraembryonic repopulating
cell as early as E9.5 in some embryos.
Neonates Are Not More Supportive for Engraftment
of Adult-like HSCs
We next determined if the neonate is a more permissive recipient
for all HSCs or only those from the early embryo. Long-term
(LT)-HSCs (lineage Sca1+ c-Kit+ CD150+ CD48) from adult
BM (Kiel et al., 2005)were transplanted intoneonatal andadult re-
cipients indoses ranging from100 to10cells (Figure 1EandTable
S1). Surprisingly, adult donor LT-HSCs failed togive rise to robust
engraftment in neonatal recipients monitored for up to 23 weeks.
Adult recipients were robustly engrafted, whereas engraftment in
neonatal recipients was minimal. At 18 weeks posttransplant, all
adult recipients that received 100 cells and three of five animals
that received ten cells showed multilineage engraftment. LDA
from adult recipients predicted one repopulating cell in 13.1 LT-
HSCs from adult BM (Table 1), which is less frequent than pub-
lished reports that used 200,000 helper cells (Kiel et al., 2005).
While considering low-level engraftment of neonates, LDA pre-
dicted one repopulating cell in 177 LT-HSCs (Table 1).
We mined published microarray data of HSCs from E11.5
AGM and adult BM to better understand why HSCs from
different developmental stages might prefer different transplant
hosts (McKinney-Freeman et al., 2012). Modules from themicro-
array data point to key differences in cytokine-cytokine receptor
interaction, transcription, metabolism, the toll-like receptor
signaling pathway, and membrane composition. With 324 differ-
entially expressed genes encoding membrane proteins, welopmental Cell 29, 621–628, June 9, 2014 ª2014 Elsevier Inc. 623
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to unique niches in different hematopoietic tissues. Interestingly,
all examined genes known to be involved in homing (cxcr4,
cd44, connexin-43, cd49d, lfa-1, and psgl1) showed consistent
expression between E11.5 AGM HSCs and adult BM HSCs.
To determine if a mature definitive HSC population from the
FL could engraft neonates, we transplanted cells with the
same surface antigen profile (lineage Sca1+ c-Kit+ CD150+
CD48) from E14.5 FL into neonatal and adult recipients in doses
ranging from 100 to 10 cells (Figure 1F and Table S1). Adult
recipients had high-level engraftment at all doses, whereas
neonatal engraftment was only robust with 100 donor cells. At
18 weeks posttransplant, ten of 16 neonatal recipients that
received 100 cells showed balanced multilineage reconstitution
with an average of 22.7% donor contribution, whereas only one
of eight neonates transplanted with 50 cells, two of six trans-
planted with 25 cells, and one of eight transplanted with ten cells
were engrafted. LDA from neonatal recipients predicted one re-
populating cell in 114 LT-HSCs, whereas from adult recipients
LDA predicted one repopulating cell in 25.7 LT-HSCs (Table 1).
Thus, whereas E14.5 FL LT-HSCs engrafted neonates more
readily than adult BM LT-HSCs, both classes of definitive LT-
HSCs from FL and adult BM engrafted better in irradiated adults
than in neonates.
To further examine the differences between HSCs residing in
the liver versus the BM, we transplanted LT-HSCs from neonatal
BMand neonatal liver into neonates. At 18weeks posttransplant,
we observed a difference in the engraftment potential; more an-
imals were engrafted at higher levels with neonatal liver LT-HSCs
(Figure 1G and Table S1). These data demonstrate a decrease in
neonatal engraftment potential in HSCs residing in the BM,
whether neonatal or adult.
Improving Neonatal Engraftment Potential of Adult BM
HSCs
We observed more robust engraftment in neonates transplanted
with FL LT-HSCs compared to BM LT-HSCs. FL LT-HSCs are
rapidly cycling and expanding in the developing embryo, while
adult BM LT-HSCs are typically quiescent (Bowie et al., 2007b;
Cheshier et al., 1999; Harrison et al., 1997; Morrison et al.,
1995). Thus, we tested whether proliferation status could influ-
ence the potential for definitive adult-like HSCs to engraft neo-
nates. To drive adult-like HSCs into the cell cycle, we treated
adult mice with interferon-a (IFNa) and 5-flurouracil (5-FU;
Essers et al., 2009; Randall and Weissman, 1997; Sato et al.,
2009; Venezia et al., 2004). Cycling HSCs were then isolated
and transplanted into neonatal recipients (Figure S3A). HSCs
exposed to IFNa were able to engraft neonates and adults
more robustly than PBS-treated controls (Figure 2A). When
HSCs were exposed to 5-FU, which has less effect on quiescent
HSCs than IFNa (Lerner and Harrison, 1990), we observed no
enhancement of neonatal engraftment (Figure S3B). Further
analysis of FL HSCs and BM HSCs treated with IFNa and 5-FU
through published microarrays revealed 43 upregulated genes
common between FL HSCs and IFNa-treated HSCs (Figures
2B and 2C). The gene-ontogeny categories of the commonly
upregulated genes are biological processes essential for pro-
liferation (Figure 2D). Gene-set enrichment analysis showed
that 5-FU-treated HSCs do not upregulate the same genes624 Developmental Cell 29, 621–628, June 9, 2014 ª2014 Elsevier Inas IFNa-treated HSCs or FL HSCs (Figure S3C), suggesting
IFNa and 5-FU have disparate effects on HSCs, which may
explain the difference in neonatal engraftment potential. Adult
BM HSCs exposed to granulocyte colony-stimulating factor,
another treatment associated with HSC mobilization and acti-
vation of HSC cycling, likewise upregulates the commonly
upregulated genes in FL and IFNa-treated HSCs (Figure S3D).
We also observed that more neonatal liver LT-HSCs are pro-
liferating than neonatal BM LT-HSCs, suggesting that neonatal
engraftment potential as well as proliferation decreases around
birth in HSCs that have migrated to the BM (Figure 2E). Collec-
tively, these data suggest that an active cell cycle enhances
neonatal engraftment; however, additional elements are also at
work.
LT-HSCs Home to Different Recipient Tissues in
Neonates versus Adults
We also hypothesized that HSCs from different developmental
stages home to different hematopoietic tissues in neonates
and adults, which likely has a significant impact on long-term
engraftability. We transplanted LT-HSCs from adult BM into
neonatal or adult recipients, and after 15 hr recovered and disso-
ciated multiple tissues and surveyed for donor cells by flow
cytometry. We chose to examine the recipients 15 hr postinjec-
tion to assess homing prior to proliferation of the donor cells
(Driessen et al., 2003; Hendrikx et al., 1996; Nilsson et al.,
1997). At 15 hr posttransplant, we detected comparable
numbers of donor cells in both neonates and adults, indicating
that a lack of short-term donor cell survival could not account
for the failure of adult LT-HSCs to engraft in neonates. In adult
recipients, 42% of injected cells were detected in the liver,
48% in the spleen, and 8.7% in the marrow of the leg bones.
In neonatal recipients, 88% of injected cells were detected in
the liver, 4.3% in the spleen, and 6.9% in the marrow of the leg
bones. Very few or no donor cells were found in the thymus, pe-
ripheral blood, or lungs of either adults or neonates (Figure 3).
These data demonstrate that definitive adult-like HSCs home
to different tissues in neonates relative to adult recipients, which
may underscore the difference observed in long-term engraft-
ment. We also assayed the homing of VE-cadherin+ CD45+ cells
from E11.5 AGM but were unable to detect any donor cells at
15 hr posttransplant. This suggests few early embryonic HSCs
survive 15 hr posttransplant, and those that survive to contribute
to reconstitution are too few to detect.
DISCUSSION
Although prior literature suggests that the neonate harbors a
more permissive environment for engraftment of early HSCs
(Yoder and Hiatt, 1997; Yoder et al., 1997b) and microarray
data of early and adult-like HSCs show differentially expressed
genes with various functional roles (McKinney-Freeman et al.,
2012), there have been no prior reports directly comparing and
quantifying the repopulating cell frequency of HSCs from multi-
ple points during ontogeny in both neonatal and adult recipients.
Here, we highlight the importance of the recipient in determina-
tion of engraftment outcomes, and identify several perplexing
differences between the capacity of nascent embryonic and
definitive adult-like HSCs to engraft either neonates or adults.c.
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Figure 2. Cycling Adult LT-HSCs Engraft
Neonates
(A) Neonatal and adult recipients were trans-
planted with 100 BM LT-HSCs from adult mice
treated with IFNa (square) or PBS (circle). Data
shown are at 18 weeks posttransplantation. Using
Fisher’s exact test to compare the percent of ani-
mals engrafted, the p value is 0.5581, whereas
using Student’s t test to compare the average
percent engraftment, the p value is 0.1730.
(B) Depiction of overlap of upregulated genes in
IFNa-treated bone-marrow HSCs (Essers et al.,
2009) and FL HSCs (McKinney-Freeman et al.,
2012) when compared to untreated bone-marrow
HSCs. Significance of overlap was determined via
the hypergeometric test.
(C) List of commonly upregulated genes.
(D) Top 10 gene-ontology biological processes in
commonly upregulated genes from (B).
(E) Quantification of fluorescence-activated cell
sorting analysis of Ki-67+ LT-HSCs in neonatal liver
and BM. Data shown are the mean ± SEM of three
experimental replicates with pooled samples.
Paired t test value = 0.065. See also Figure S3.
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suited to engraftment in neonates; conversely, definitive adult-
like HSCs, whether harvested from FL or adult BM, more effi-
ciently reconstitute adult hosts. We used the neonatal transplant
model to better understand the engraftment requirements of
adult HSCs and identified two factors that may modulate
neonatal engraftment potential, differential proliferative activity,
and homing potential. The neonatal transplant assay provides
a tool to further our understanding of the factors required for
survival, maturation, and function of embryonic HSCs and
can be utilized to functionally examine nascent HSC-like cells
derived from pluripotent stem cells.Developmental Cell 29, 621–Our data demonstrate robust long-
term multilineage hematopoietic recon-
stitution of unmanipulated, uncultured
E10.5 AGM in wild-type murine recipi-
ents, thereby establishing that definitive
HSCs indeed arise within the embryo at
this early stage, but a receptive host is
required to observe this functionality.
Others have shown that E10.5 AGM and
even E9.5 PSp can engraft immunodefi-
cient adult recipients, suggesting that
genetic immunodeficiency in adult recip-
ients enables the same permissiveness
to engraftment of embryonic cells as we
observe in the neonate (Bertrand et al.,
2005; Cumano et al., 2001; Kieusseian
et al., 2012; Levy, 2007; Maro´di, 2006).
Indeed, immaturity of the neonatal im-
mune system may represent a reduced
transplantation barrier for early embry-
onic HSCs, which express lower levels
of major histocompatibility complex class
I molecules, and are thus susceptible torejection by natural killer-mediated mechanisms (Cumano
et al., 2001). Interestingly, we have also shown that the neonate
is not a more permissive recipient for HSCs from all stages of
ontogeny because purified LT-HSCs from E14.5 FL and adult
BM do not engraft neonates as robustly as in adults. Adult-like
HSCs likely respond to the neonatal environment differently
than early HSCs because of the differential expression of genes
involved in cytokine-cytokine receptor interaction and mem-
brane composition. The preference of immature HSCs for
engraftment in neonates may have clinical parallels in the ten-
dency of umbilical cord blood to more robustly engraft juveniles
as compared to adults, a phenomenon that may not depend628, June 9, 2014 ª2014 Elsevier Inc. 625
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Figure 3. Homing of Adult LT-HSCs Differs in Adult and Neonatal
Recipients
Percentages of GFP+ CD45.2+ donor adult BM LT-HSCs detected in six
tissues in adult and neonatal recipients 15 hr posttransplantation. No donor
cells were found in the thymus or peripheral blood. Data shown are the
mean ± SEM, representing a total of five to six mice per condition with data
collected in experimental duplicate for adults and triplicate for neonates. Liver
and spleen p values < 0.05; lung, BM, thymus, and peripheral blood (PB)
p values > 0.05 as calculated with the Student’s t test.
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Wagner et al., 2002).
Our study suggests that HSCmigration to the BM is coupled to
limited neonatal engraftment potential. HSCs harvested from the
neonatal liver re-engraft in neonates more robustly than HSCs
harvested from the neonatal BM, indicating that either cell
intrinsic changes that trigger migration from the liver to the BM
also cause decreased neonatal engraftment, or that migration
to the BM induces an alteration in HSCs that persists as the
animal matures, because adult BM HSCs yield no or low level
engraftment in neonates. When we surveyed homing of adult
BM HSCs in neonatal and adult recipients, we found most donor
cells in the liver in neonates and the liver and spleen in adults.
Although we detected similar numbers of donor cells in neo-
nates and adults, and a comparable percent of donor cells
homed to the BM in neonates and adults 15 hr postinjection,
long-term engraftment of adult BM HSCs in neonates was very
poor. Several potential explanations can be entertained to
account for this. Coupled with our finding that FL HSCs engraft
neonates more robustly than adult BM HSCs, one possible
explanation is that the quiescent state of adult HSCs may not
be suitable for engraftment in neonatal recipients. Concentra-
tions of steel factor in neonatal hematopoietic niches may play
a role (Bowie et al., 2007a). Recent work defines two distinct
niches for cycling and quiescent HSCs in adult BM, which may
be present in different ratios or nonexistent in the developing
neonatal BM (Kunisaki et al., 2013). Additionally, our neonatal
engraftment conditions permit only sublethal doses of irradia-
tion, whereas engraftment of adults is typically measured after
lethal doses of irradiation. The sublethal irradiation of neonates
may not generate a sufficiently strong homeostatic drive to
induce substantial proliferation of the otherwise quiescent
adult HSCs, especially considering the presence of competing
actively cycling neonatal HSCs.
In conclusion, we have used the neonatal transplant model to
functionally assay the engraftment potential of emerging early
embryonic HSCs, which go undetected when using wild-type
adult recipients. Future studies using the neonatal transplant626 Developmental Cell 29, 621–628, June 9, 2014 ª2014 Elsevier Inmodel may allow us to discover new populations in hematopoi-
etic tissues from other points in ontogeny that also engraft
neonatal but not adult recipients. Additionally, neonates may
provide a unique environment to functionally assay hematopoi-
etic derivatives of pluripotent stem cells.
EXPERIMENTAL PROCEDURES
Animals
C57BL/6 and B6.SJL mice were purchased from Jackson Laboratories and
Taconic and bred in house. UBC-GFP mice were purchased from Jackson
Laboratories (strain #004353; Schaefer et al., 2001). Experiments were carried
out with Institutional Animal Care andUseCommittee approval fromChildren’s
Hospital Boston.
Bone Marrow Transplantation
Donor and recipient cells were distinguished by CD45.1 and CD45.2. Adult
recipients were either conditioned with a lethal dose of irradiation, 10 Gy total
split by 3 hr, and received 33 105 cells from whole BM as helper or sublethally
conditioned with a 3.5 Gy or 6.5 Gy dose of irradiation and did not receive
helper cells. Neonatal recipients, 1–2 days old, were conditioned with a
sublethal single dose of irradiation, 3.5 Gy, and received no helper cells.
HSC Proliferation
To induce HSC proliferation, adult mice were treated with one dose of IFNa
(10,000 units given subcutaneously) 24 hr prior to HSC isolation. Alternatively,
adult mice received one dose of 5-FU (150 mg/kg) by intraperitoneal injection
5 days prior to HSC isolation.
Homing
Approximately 104 isolated cells were transplanted into neonatal and adult
recipients. Transplanting purified LT-HSCs in addition to injecting a small num-
ber of cells reduces the likelihood of donor cells being trapped in the lung. At
15 hr postinjection, the lung, peripheral blood, spleen, liver, thymus, and BM
from the long bones of the leg were analyzed with fluorescence-activated
cell sorting.
Microarray Analysis
The microarray data were analyzed per standard protocol using R/Bio-
conductor. Data were obtained from Gene Expression Omnibus accession
numbers GSE14361 (Essers et al., 2009), GSE1559 (Venezia et al., 2004),
GSE37000 (McKinney-Freeman et al., 2012), and GSE55095 (Schuettpelz
et al., 2014).
For full details, see the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and one table and can be found with this article online at
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